Paul Laland

Supporting Accumulus CEO to create a new corporate identity and positioning platform. Accumulus is developing a global information exchange platform to transform how drug innovators and health regulators interact to bring safe and effective medicines to patients faster and more efficiently.

Established Corporate Communications and Patient Advocacy function, including a major corporate branding effort, patient education programs, community relations, internal Bonding Matters campaign and Executive thought leadership program. Communications function was eliminated as Principia was acquired by Sanofi for $3.6 billion or $100 per share.

Interim Head of function; established Corporate Communications department and team; provided strategic communications council to Executive Team.

Established and led global communications function, including media and constituency relations, a complete corporate branding initiative, and investor relations support. Member of the Executive Management team.

Started and directed new agency within W2O Group focusing on corporate communications and branding services with early stage life sciences companies.

Senior communications consultant to life sciences companies. Built team to support a $5 million corporate communications practice for life sciences companies.

Directed corporate communications function, including investor, public and advocacy relations.

Directed all media and public relations activities in support of the development of a new anthrax vaccine; a $750 million biodefense program paid by Project BioShield.

Started and built a 20 person team to support a corporate communications practice for life science companies, including investor, public and advocacy relations.